Relevant Publications

Gharaylou Z, Tafakhori A, Agah E, Aghamollaii V, Kebriaeezadeh A, Hadjighassem M. A preliminary study evaluating the safety and efficacy of bumetanide, an NKCC1 inhibitor, in patients with drug-resistant epilepsy. CNS Drugs. 2019 Mar;33(3):283-291. doi:10.1007/s40263-019-00607-5
Eftekhari S, Habibabadi JM, Ziarani MN, Fesharaki SSH, Gharakhani M, Mostafavi H, Joghataei MT, Beladimoghadam N, Rahimian E, Hadjighassem MR. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia. 2013 Jan;54(1):e9-12. doi:10.1111/j.1528-1167.2012.03654.x
Hochman DW. The extracellular space and epileptic activity in the adult brain: explaining the antiepileptic effects of furosemide and bumetanide. Epilepsia. 2012 Jun;53(suppl 1):18-25. doi:10.1111/j.1528-1167.2012.03471.x
No more Publications to show